{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:03:29Z","timestamp":1766419409068,"version":"3.48.0"},"reference-count":19,"publisher":"BMJ","issue":"7145","license":[{"start":{"date-parts":[[1998,5,30]],"date-time":"1998-05-30T00:00:00Z","timestamp":896486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[1997,12,5]]},"published-print":{"date-parts":[[1998,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To determine how small differences in the efficacy and cost of two antibiotic regimens to eradicate\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    can affect the overall cost effectiveness of\n                    <jats:italic>H pylori<\/jats:italic>\n                    eradication in duodenal ulcer disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design:<\/jats:bold>\n                    A decision analysis to examine the cost effectiveness of eight\n                    <jats:italic>H pylori<\/jats:italic>\n                    eradication strategies for duodenal ulcer disease with and without\n                    <jats:sup>13<\/jats:sup>\n                    C-urea breath testing to confirm eradication.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measures:<\/jats:bold>\n                    Cumulative direct treatment costs per 100 patients with duodenal ulcer disease who were positive for\n                    <jats:italic>H pylori.<\/jats:italic>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In model 1 the strategy of omeprazole, clarithromycin, and metronidazole alone was the most cost effective of the four strategies assessed. The addition of the\n                    <jats:sup>13<\/jats:sup>\n                    C-urea breath test and a second course of omeprazole, clarithromycin, and metronidazole achieved the highest eradication rate (97%) but was the most expensive (\u00a362.63 per patient). The cost of each additional effective eradication was \u00a3589.00 (incremental cost per case) when compared with the cost of treating once only with omeprazole, clarithromycin, and metronidazole; equivalent to the cost of a patient receiving ranitidine for duodenal ulcer relapse for more than 15 years. Eradication strategies of omeprazole, amoxycillin, and metronidazole were less cost effective than omeprazole, clarithromycin, and metronidazole alone. In model 2 the addition of the\n                    <jats:sup>13<\/jats:sup>\n                    C-urea breath test after treatment, and maintenance treatment, increased the cost of all the strategies and reduced the cost advantage of omeprazole, clarithromycin, and metronidazole alone.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Small differences in efficacy can influence the comparative cost effectiveness of strategies for eradicating\n                    <jats:italic>H pylori<\/jats:italic>\n                    . Of the strategies tested the most cost effective (omeprazole, clarithromycin, and metronidazole alone) was neither the least expensive (omeprazole, amoxycillin, and metronidazole alone) nor the most effective (omeprazole, clarithromycin, and metronidazole with further treatment for patients found positive for\n                    <jats:italic>H pylori<\/jats:italic>\n                    on\n                    <jats:sup>13<\/jats:sup>\n                    C-urea breath testing). Cost effectiveness should be an important part of choosing an eradication strategy for\n                    <jats:italic>H pylori<\/jats:italic>\n                    .\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:boxed-text position=\"float\">\n                      <jats:sec>\n                        <jats:title>Key messages<\/jats:title>\n                        <jats:list list-type=\"bullet\">\n                          <jats:list-item>\n                            <jats:p>It is unlikely that randomised controlled trials to examine the effect of small differences in efficacy and cost between eradication regimens will ever be performed because of the large numbers of patients required<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:p>\n                              Decision analysis models show that relatively small differences in efficacy and cost between several strategies for eradication of\n                              <jats:italic>H pylori<\/jats:italic>\n                              in patients with duodenal ulcer disease lead to large differences in their relative cost effectiveness\n                            <\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:p>\n                              The most cost effective strategy was neither the least expensive nor the most effective for eradication of\n                              <jats:italic>H pylori<\/jats:italic>\n                            <\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:p>\n                              For uncomplicated duodenal ulcer disease performing a\n                              <jats:sup>13<\/jats:sup>\n                              C-urea breath test to identify patients failing eradication treatment is not cost effective if patients only receive acid suppression treatment for relapses that produce symptoms\n                            <\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:p>\n                              Performing a\n                              <jats:sup>13<\/jats:sup>\n                              C-urea breath test to identify patients failing eradication treatment may only be cost effective in high risk patients\n                            <\/jats:p>\n                          <\/jats:list-item>\n                        <\/jats:list>\n                      <\/jats:sec>\n                    <\/jats:boxed-text>\n                  <\/jats:p>","DOI":"10.1136\/bmj.316.7145.1648","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:52:58Z","timestamp":1319745178000},"page":"1648.1-1654","source":"Crossref","is-referenced-by-count":21,"title":["Varying efficacy of\n                    <i>Helicobacter pylori<\/i>\n                    eradication regimens: cost effectiveness study using a decision analysis modelCommentary: Helicobacter pylori eradication in primary care"],"prefix":"10.1136","volume":"316","author":[{"given":"A E","family":"Duggan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan C","family":"Delaney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Tolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Hawkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R F A","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F D Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1998,5,30]]},"reference":[{"key":"2025122208001046000_316.7145.1648.1","unstructured":"Logan RPH . Eradication of Helicobacter pylori: which regimen, which patients? In: Farthing MJG , ed. Clinical challenges in gastroenterology. London: Martin Dunitz, 1996:42\u201342."},{"key":"2025122208001046000_316.7145.1648.2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","article-title":"Treatment of Helicobacter pylori: a review of the world literature","volume":"1","author":"van der Hulst","year":"1996","journal-title":"Helicobacter"},{"key":"2025122208001046000_316.7145.1648.3","unstructured":"Sugden R Williams A . The principles of practical cost-benefit analysis. Oxford University Press: Oxford, 1978."},{"key":"2025122208001046000_316.7145.1648.4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2165\/00019053-199711030-00003","article-title":"Is Helicobacter pylori eradication cost-effective treatment of duodenal ulcer disease?","volume":"11","author":"Carrere","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"2025122208001046000_316.7145.1648.5","first-page":"45","article-title":"Clinical and pharmacological evaluation of management for duodenal ulcer disease","volume":"6","author":"Bell","year":"1993","journal-title":"Br J Med Econ"},{"key":"2025122208001046000_316.7145.1648.6","first-page":"A37","article-title":"Cost-impact of clarithromycin plus omeprazole compared to traditional therapies for treatment of H pylori associated duodenal ulcers","volume":"39","author":"Sonnenberg","year":"1996","journal-title":"Gut"},{"key":"2025122208001046000_316.7145.1648.7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0016-5085(89)90511-8","article-title":"Costs of medical and surgical treatment of duodenal ulcer","volume":"96","author":"Sonnenberg","year":"1989","journal-title":"Gastroenterology"},{"key":"2025122208001046000_316.7145.1648.8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0016-5085(90)91225-U","article-title":"Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer","volume":"99","author":"Pym","year":"1990","journal-title":"Gastroenterology"},{"key":"2025122208001046000_316.7145.1648.9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(81)90128-8","article-title":"Model of medical treatment for duodenal ulcer","volume":"i","author":"Pounder","year":"1981","journal-title":"Lancet"},{"key":"2025122208001046000_316.7145.1648.10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2036.1993.tb00096.x","article-title":"A placebo controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine","volume":"7","author":"Penston","year":"1993","journal-title":"Alimentary Pharmacol Ther"},{"key":"2025122208001046000_316.7145.1648.11","first-page":"A166","article-title":"What is the relevance of the randomised controlled trial in H. pylori eradication to routine clinical practice?","volume":"41","author":"Johnston","year":"1997","journal-title":"Gut"},{"key":"2025122208001046000_316.7145.1648.12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00019053-199609020-00003","article-title":"The decision rules of cost-effectiveness analysis","volume":"9","author":"Karlsonn","year":"1996","journal-title":"Pharmacoeconomics"},{"key":"2025122208001046000_316.7145.1648.13","first-page":"835","article-title":"Efficacy and optimum dose of omeprazole in a new 1 week triple therapy regimen to eradicate Helicobacter pylori","volume":"7","author":"Moayyedi","year":"1995","journal-title":"Euro J Gastroenterol Hepatol"},{"key":"2025122208001046000_316.7145.1648.14","unstructured":"Lamouliatte H Cayla R Talbi P Zerbib F Megraud F . Randomized study comparing two seven days triple therapies with lanzoprazole and low dose of clarythromycin plus amoxycillin or tinidazole for Helicobacter pylori eradication. Gastroenterology 1996; 110: A170."},{"key":"2025122208001046000_316.7145.1648.15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/135581969600100208","article-title":"\u201cEvidence-based, cost-effective\u201d and \u201cpreference-driven\u201d medicine: decision analysis based medical decision making is the pre-requisite","volume":"1","author":"Dowie","year":"1996","journal-title":"J Health Serv Res Policy"},{"key":"2025122208001046000_316.7145.1648.16","first-page":"1716","article-title":"Meta analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori","volume":"87","author":"Chiba","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"2025122208001046000_316.7145.1648.17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/bmj.312.7042.1321","article-title":"Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic symptoms in patients under 45 years of age","volume":"312","author":"Briggs","year":"1996","journal-title":"BMJ"},{"key":"2025122208001046000_316.7145.1648.18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/bmj.312.7027.349","article-title":"The absence of dyspeptic symptoms as a test for successful Helicobacter pylori eradication","volume":"312","author":"Phull","year":"1996","journal-title":"BMJ"},{"key":"2025122208001046000_316.7145.1648.19","first-page":"177","article-title":"The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting","volume":"46","author":"Rosengren","year":"1996","journal-title":"Br J Gen Pract"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.316.7145.1648","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.316.7145.1648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:00:32Z","timestamp":1766419232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.316.7145.1648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5,30]]},"references-count":19,"journal-issue":{"issue":"7145","published-online":{"date-parts":[[1998,5,30]]},"published-print":{"date-parts":[[1998,5,30]]}},"alternative-id":["10.1136\/bmj.316.7145.1648"],"URL":"https:\/\/doi.org\/10.1136\/bmj.316.7145.1648","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1998,5,30]]}}}